News

Neurocrine Biosciences Shares Insights at November Conferences

Neurocrine Biosciences Shares Insights at November Conferences

Neurocrine Biosciences to Participate in Investor Conferences

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) is gearing up for a significant presence at a series of prominent investor conferences this coming November. The company has made waves in the biotechnology sector, and these engagements aim to showcase their commitment to advancing neuroscience and improving patient care.

Schedule of Conferences

The exciting events where the Neurocrine team will share their insights include:

2024 UBS Global Healthcare Conference

On November 12, leaders from Neurocrine will present at the highly anticipated 2024 UBS Global Healthcare Conference. CEO Kyle Gano, CFO Matt Abernethy, and Vice-President of Investor Relations Todd Tushla are set to delve into the company’s strategic direction and recent advancements in their treatment offerings. This presentation is scheduled for 1:15 PM Pacific Time, engaging investors with valuable information on Neurocrine's future.

Stifel 2024 Healthcare Conference

Following closely is the Stifel 2024 Healthcare Conference on November 18. Here, also at 10:55 AM Eastern Time, CFO Matt Abernethy, alongside Chief Commercial Officer Eric Benevich, will provide insights into Neurocrine's financial health and commercial strategies. Their discussions will focus on innovative approaches to treatment and business growth.

Jefferies London Healthcare Conference

Concluding this series of presentations, the Jefferies London Healthcare Conference will take place on November 19 at 1:30 PM GMT. This panel will feature CEO Kyle Gano, CFO Matt Abernethy, along with Chief Medical Officer Eiry Roberts. The aim here is to connect with global investors and stakeholders, sharing progress on transformative healthcare initiatives.

Webcast Availability

All presentations will be available via live webcast. Interested investors and stakeholders can access the streams through the Neurocrine Biosciences website. Following the live events, replays will be available approximately one hour after the conclusion and will remain accessible for about a month—a great opportunity for those unable to attend the live sessions.

About Neurocrine Biosciences

Neurocrine Biosciences is at the forefront of neuroscience-focused biopharmaceutical development. The company is dedicated to addressing pressing neurological, neuroendocrine, and neuropsychiatric issues faced by patients today. Neurocrine actively seeks to develop innovative therapeutic solutions, illustrated by its portfolio that includes FDA-approved treatments for conditions such as tardive dyskinesia and chorea associated with Huntington's disease.

The company has been diligently working on advancing its pipeline, which showcases several compounds currently in mid- to late-phase clinical development. By leveraging their extensive research in neuroscience, Neurocrine aims to provide significant relief to those suffering from debilitating conditions, underpinned by their mantra, "You Deserve Brave Science." For more details about their mission and developments, visitors can explore their website.

Frequently Asked Questions

1. What is the purpose of Neurocrine’s participation in conferences?

Neurocrine attends these conferences to present their advancements in neurobiopharmaceuticals and to engage with investors on their strategic vision.

2. How can I access the live presentations from these conferences?

The live presentations are accessible via the Neurocrine Biosciences website under the Investors section.

3. Which key executives will represent Neurocrine at the conferences?

CEO Kyle Gano, CFO Matt Abernethy, and CMO Eiry Roberts are among the key executives participating in these events.

4. What does Neurocrine Biosciences focus on?

Neurocrine focuses on developing treatments for neurological disorders and is committed to addressing under-treated conditions in this field.

5. What should potential investors know about Neurocrine?

Investors should recognize Neurocrine as a leader in biopharmaceutical innovation, dedicated to improving patient outcomes through cutting-edge research and development.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

ASCEND® Cladding Unveils New Profiles & Texture Variety

Updated Category News Views 0

New Options for Creative Home Exteriors Amid today's housing market rollercoaster, a sprinkle of bold innovation in building materials can make a statement—and that's precisely what Associated Materials Innovations (AMI) is banking on with their latest beef-up in the ASCEND® Composite Cladding lineup. Introduced out of Cuyahoga Falls on Sept. 8, 2026, this expansion...

Continue Reading
Hanover Unveils Skinny Veg® for GLP-1 Dieters

Updated Category News Views 1

Seems like Hanover Foods is turning heads with their move into the ever-demanding health-conscious market. This family's stepping into the limelight with their new Skinny Veg® line, clearly targeting folks riding the GLP-1 wave. You see, it's not every day that a company that's been around the block since 1924 shakes things up like this. Simplicity is the Name of the...

Continue Reading
AI Startup Shuttlebase Navigates Name Clash with Change

Updated Category News Views 1

When Two AI Giants Collide Every so often, we get a clash of titans in the business world, and this time it's in the AI universe. New York's Moonshot AI, a champ in autonomous website optimization, hit a bump when its name collided with a Chinese counterpart, also called Moonshot AI. And just like that, the NY company had to chuck their name out the window and don a new...

Continue Reading
IDX Expands, Enhances Team Amid 56% H1 Growth

Updated Category News Views 1

IDX's Aggressive Global Expansion Here's a tip from a trader who’s seen cycles rise and fall: watch the movers who're playing the long game, putting down roots worldwide while making headway in the data game. IDX has clearly mapped out this trajectory as evidenced by its recent grab in the global strategic communications ring. IDX's bustling around like a squirrel...

Continue Reading
Muscle Car Fever Revs Up in New Global TV Series

Updated Category News Views 1

Chasing the Dream on Wheels Amid the buzz of New York, there's a roar building up that's hard to ignore. It's a sound that echoes through time, capturing the imagination of petrol heads everywhere—those legendary American muscle cars are back in the limelight. I mean, who hasn't dreamt of launching down a highway in a '69 Ford Mustang? 'The Hunt for Rolling Treasure' is...

Continue Reading
How Timekettle Is Bridging Language Gaps at IFA 2026

Updated Category News Views 4

Pioneering AI Innovations in Language Translation Timekettle is making some serious waves at IFA 2026, throwing its hat in the ring with innovations that redefine multilingual interaction. From sleek translation earbuds to full-blown meeting hubs, each gadget screams one thing loud and clear—communication sans language barriers. Centered in the tech extravaganza of...

Continue Reading
Big Wins at Americas Cardroom's $15M Venom Series

Updated Category News Views 2

High Stakes and Huge Paydays: The Venom Breakdown Alright, folks, here's a tale of how the cards fell in one of the most electrifying poker standoffs at Americas Cardroom. With prize pools clocking in at a staggering $15.095 million, the Dual Mystery Bounty Venoms really stacked the chips high. From the gritty, bustling halls of the internet to the proverbial green-felt...

Continue Reading
Goodwill's ReThink Fashion: Textiles to Runway Art

Updated Category News Views 1

Transforming Old to New on the Runway Right when you think fashion's all about the next shiny thing, here comes Goodwill of Delaware & Delaware County flipping the script. Their ReThink Fashion Show - the ECO Edit teaches us a thing or two about what giving old clothes a new life truly means. It's not just about tossing a used tee onto a catwalk but a whole rebirth...

Continue Reading
Illinois' Legal Tangle: Feds Under Fire?

Updated Category News Views 2

What a tangled web Illinois lawmakers have woven this time. They've gone and cooked up a pair of laws with a real knack for attracting attention—specifically from the folks over at the National Police Association (NPA). These aren’t your run-of-the-mill rules; they feel more like a blueprint for putting federal officers through the legal wringer and turning courtroom...

Continue Reading
India's First Upright Proton Therapy System Unveiled

Updated Category News Views 4

A Leap Forward in Cancer Care: Proton Therapy Revolution Dang, just when you think you've heard it all in cancer treatment, Fortis Healthcare drops a bombshell: India’s first upright proton therapy system. Boom! This isn't your run-of-the-mill radiation treatment we're talking about here. This is the futuristic flair of the MEVION S250-FIT™, featuring upright...

Continue Reading

Top 5 Most Recently Viewed Articles

Lamar Advertising Company Declares Robust Cash Dividend for Investors

Updated Category News Views 112

Lamar Advertising Company's Commitment to Shareholders Lamar Advertising Company, a prominent name in the outdoor advertising sector, has declared an impressive quarterly cash dividend of $1.55 per share. This announcement highlights the company’s commitment to its shareholders and its robust financial performance in recent months. The dividend is set to be paid on a...

Continue Reading
Legal Battle Heats Up: JPMorgan vs. VTB Bank Lawsuits

Updated Category News Views 322

JPMorgan Entities Secure Temporary Injunction Against VTB Bank In a significant legal update, JPMorgan Emerging Europe, Middle East & Africa Securities PLC (LSE:JEMA) has been actively involved in ongoing legal proceedings with Russia's VTB Bank. This dispute arises from two lawsuits initiated by VTB Bank in Russia, wherein the bank seeks claims totaling approximately...

Continue Reading
Bank of America's Low Valuation and Future Growth Prospects

Updated Category News Views 109

Bank of America’s Strong Performance in the Market Financial giant Bank of America Corp has showcased a remarkable performance trajectory, especially evident at the start of a new trading period. Stocks saw an impressive rally, hitting record highs and maintaining a robust position as the market transitioned into the new year. However, following a recent earnings...

Continue Reading
Revitalization: Morgan's Blueprint for Lasting Impact

Updated Category News Views 2

Reimagining Revitalization: Beyond Bricks and Mortar Hold onto your blueprints, folks, because Robert "Bob" Morgan's got a different story to tell about real estate development. Sure, we love a shiny new skyscraper, but Morgan, the man behind Morgan Communities, argues that true revitalization isn't just about plopping down new buildings. It's about respecting the people...

Continue Reading
Interest Rate Cuts: A Global Shift Towards Easing Policies

Updated Category News Views 88

Understanding the Shift in Global Monetary Policy The European Central Bank (ECB) is anticipated to announce a notable interest rate cut in the near future. Many analysts see this as part of a larger trend toward synchronized monetary easing worldwide. This shift is a response to the evolving economic environment, as central banks modify their strategies to encourage...

Continue Reading